Post a Comment Print Share on Facebook
Featured Caser Aragonès Japón Contaminación LOréal

RELEASE: Tetra Pharm Technologies and Glysious collaborate to develop transdermal combination drugs

(Information sent by the signatory company).

- 4 reads.

RELEASE: Tetra Pharm Technologies and Glysious collaborate to develop transdermal combination drugs

(Information sent by the signatory company)

- Tetra Pharm Technologies and Glysious announce collaboration to develop transdermal combination drugs targeting the endocannabinoid system

Collaboration brings together Tetra Pharm Technologies' expertise in training technology with Glysious' patented transdermal drug delivery system, known for its effectiveness, comfort and convenience

COPENHAGEN, Denmark, April 24, 2024 /PRNewswire/ -- Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration to develop an innovative transdermal drug delivery system that complements several of Tetra Pharm's pipeline candidates Technologies. The joint invention aims to revolutionize the transdermal delivery of “difficult to formulate” compounds targeting the endocannabinoid system.

Tetra Pharm Technologies has focused intensely on formulation insights, that is, how molecules are effectively integrated with a drug delivery system to achieve desired targets. Glysious has been rigorously working on the development of an adhesive patch for transdermal drug delivery since the company's incorporation in 2020.

"Glysious technology allows for precise and sustained dosing, as well as high drug loading and efficient emptying of the patches. The transdermal patches remain in place and are very comfortable and practical to use, which improves therapeutic compliance. However, we have detected problems with standard formulation strategies, which do not provide acceptable drug release due to deficiencies in the formulation matrix," said Professor and Dr. Techn. Anne Ladegaard Skov, scientific director of Glysious.

In 2023, Glysious and Tetra Pharm Technologies conducted the first in vitro feasibility tests, integrating Tetra Pharma Technologies' proprietary technology for the delivery of poorly soluble compounds with the Glysious patch.

Dr. Morten Allesø, Chief Scientific Officer at Tetra Pharm Technologies, added: "While we were both aware of the uniqueness of our respective technologies, we were positively surprised to see a five-fold increase in the performance of our combined product compared to conventional formulation technologies. "This is truly remarkable, and we see it as our shared obligation to continue advancing this technology for the benefit of patients."

The objectives of the collaboration include conducting extensive in vitro and in vivo studies to evaluate the performance and efficacy of the combined drug delivery system. In addition, Tetra Pharm Technologies and Glysious plan to apply for a common patent for the joint invention, thus guaranteeing the protection and exclusivity of their innovative technology.

"We are delighted to collaborate with the innovative team at Tetra Pharm Technologies on this transdermal drug delivery system that paves the way for the commercialization and scale-up of Glysious technology in the pharmaceutical sector," explained Stina Bjerg Nielsen, CEO of Glysious.

Martin Rose, CEO of Tetra Pharm Technologies, highlighted: "The collaboration represents a unique opportunity to leverage the synergies between our respective technologies. By combining our expertise, we aim to develop a transdermal drug delivery system that offers greater efficacy, convenience and compliance by part of the patient, in support of several of our programs in development phase.

As part of the collaboration, the partners will exchange experience, knowledge and resources. In addition, Tetra Pharm Technologies and Glysious will conduct joint research, experiments and testing, as necessary for the development of a joint patent. The scope of the collaboration focuses on disease indications such as pain, sleep disorders and appetite regulation.

About Tetra Pharm Technologies

Tetra Pharm Technologies is a Danish biopharmaceutical company created in 2018 with the vision of being a leader in research and development of drugs for the treatment of diseases related to the endocannabinoid system. For more information, visit

About Glysious

Glysious is a Danish medical technology company, incorporated in 2020, that develops patches, creams, sprays and foams with controlled release of active ingredients for cosmetic and life science applications. For more information, visit

For more informationJacob SchlundtMarketing ManagerTetra Pharm 45 51976225

Stina Bjerg NielsenConsejero 45 3053 5393

Photo - -

View original content: